BLOCKADE OF THE PD‐1 CHECKPOINT WITH ANTI–PD‐L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL). (June 2017) - Chen, R.; Gibb, A.L.; Collins, G.P.; Popat, R.; El‐Sharkawi, D.; Burton, C.; Lewis, D.; Miall, F.M.; Forgie, A.; Compagnoni, A.; Andreola, G.; Brar, S.; et al.